<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000397115"><TermName>panitumumab</TermName><TermPronunciation>(PAN-ih-TOO-myoo-mab)</TermPronunciation><TermDefinition><DefinitionText>A human monoclonal antibody that is being used to treat colorectal cancer that has spread to other parts of the body. It is used in patients whose disease has not gotten better during or after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Panitumumab binds to the epidermal growth factor receptor (EGFR) and may block tumor cell growth. Also called ABX-EGF and Vectibix.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000713437" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;panitumumab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000713436" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;panitumumab&quot;" language="es" id="_4"/><SpanishTermName>panitumumab</SpanishTermName><SpanishTermDefinition><DefinitionText>Anticuerpo monoclonal humano que se usa para el tratamiento de cáncer colorrectal que se diseminó a otras partes del cuerpo. Se administra a pacientes cuya enfermedad no mejoró durante el tratamiento con otros medicamentos contra el cáncer o después de este. Asimismo, está en estudio para el tratamiento de otros tipos de cáncer. Los anticuerpos monoclonales se producen en el laboratorio y pueden localizar sustancias en el cuerpo y unirse a ellas, incluso a las células cancerosas. El panitumumab se une al receptor del factor de crecimiento epidérmico (EGFR) y podría bloquear el crecimiento de células tumorales. También se llama ABX-EGF y Vectibix.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2005-06-25</DateFirstPublished><DateLastModified>2008-11-14</DateLastModified><RelatedInformation><RelatedDrugSummaryRef href="CDR0000511994">Panitumumab</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
